Peter Diamandis

Rank 8 of 47
|
Score 126
5/18/2024, 2:44:36 AM
X
In reply to:
Peter H. Diamandis, MD
@PeterDiamandis
·
498d
It also demonstrated a robust application in clinical trials by potentially cutting down the costs of identifying patients who will benefit from new treatments by half!
Peter H. Diamandis, MD
@PeterDiamandis
·
498d
The results are that it significantly reduces the cost and scale of data required for traditional brain studies.
Peter H. Diamandis, MD
@PeterDiamandis
·
498d
The model, known as BrainLM, leverages 80,000 scans from 40,000 subjects to capture the dynamics of brain activity with no need for specific disease-related data.
Peter H. Diamandis, MD
@PeterDiamandis
·
498d
A team of researchers at Baylor College of Medicine and Yale University incorporated generative artificial intelligence to develop a foundational model for brain activity.
Peter H. Diamandis, MD
@PeterDiamandis
·
498d
We are about to enter a new era in Neuroscience with Generative AI, here’s how:

The statement in question is part of a larger conversation about advancements in neuroscience and the application of generative AI in medical research. The initial tweets by @PeterDiamandis discuss significant scientific developments and their implications for the field. However, the specific statement promoting the 'Longevity Insider' newsletter, while linked to the topic of biotech news, primarily serves as a promotional tool rather than engaging substantively with the public discourse initiated by @PeterDiamandis. It does not delve into the specifics of the research or its implications but rather invites readers to subscribe to a newsletter related to the broader field of biotech and longevity.